ArticleSkeletal radiology2026
Genicular artery embolization as a minimally invasive treatment for knee osteoarthritis: systematic review and meta-analysis.
Article in Skeletal radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesGenicular artery embolization (GAE) has emerged as a novel intervention targeting the inflammatory cycle of knee osteoarthritis (KOA). While previous meta-analyses established efficacy, they were limited by small samples and embolic protocols. This systematic review incorporates recent trials and techniques, emphasizing on longitudinal improvement and durability of response. MATERIALS AND
methodsA systematic search of PubMed, EMBASE, and Cochrane Central was conducted from inception through October 2025. Studies reporting patient-reported outcomes (VAS, WOMAC, KOOS) were included. Data were pooled using random-effects models to quantify changes from baseline. Heterogeneity was assessed using I
resultsA total of 18 studies comprising 534 patients demonstrated significant and sustained pain reduction, with mean VAS decreases of 3.96 (95% CI - 4.64 to - 3.27), 4.17 (95% CI - 4.81 to - 3.54), 4.36 (95% CI - 5.09 to - 3.63), and 4.53 (95% CI - 5.47 to - 3.60) points at 1, 3, 6, and 12 months, respectively. WOMAC and KOOS outcomes followed similar trajectories with improvements at 1 month and maintained through 12-month follow-up. Magnitude of VAS improvement exceeded commonly accepted clinically thresholds across all time points. Substantial heterogeneity (I
conclusionsGAE provides meaningful and durable symptom relief for KOA refractory to conservative management. However, substantial heterogeneity and recent sham-controlled data indicate that the magnitude of treatment effect remains uncertain. These findings support standardization of protocols, selection criteria, and outcome reporting in future studies.
Indexed as
Identifiers
42573777What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.